

01-24-05

IFW



Application No. (if known): 10/823,396

Attorney Docket No.: 05986/100M724-US1

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. \_\_\_\_\_ in an envelope addressed to:

**EV 329021433 - us**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on January 21, 2005  
Date

*B.W. Lee*

Signature

**B.W. LEE**

Typed or printed name of person signing Certificate

@@@

Registration Number, if applicable

(212) 527-7700

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal (1 page)  
Information Disclosure Statement (2 pages)  
IDS (Citation) by Applicant (3 pages) along with 35 References  
Return Receipt Postcard

**TRANSMITTAL  
FORM***(to be used for all correspondence after initial filing)*

Total Number of Pages in This Submission

7

Application Number

10/823,396

Filing Date

April 12, 2004

First Named Inventor

Marcus B. Jones

Art Unit

1632

Examiner Name

Not Yet Assigned

Attorney Docket Number

05986/100M724-US1

**ENCLOSURES (Check all that apply)**☐ Fee Transmittal Form☐ Fee Attached☐ Amendment/Reply☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☒ Information Disclosure Statement☐ Certified Copy of Priority Document(s)☐ Reply to Missing Parts/  
Incomplete Application☐ Reply to Missing Parts under  
37 CFR 1.52 or 1.53☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a  
Provisional Application☐ Power of Attorney, Revocation  
Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s) \_\_\_\_\_☐ Landscape Table on CD☐ After Allowance Communication  
to TC☐ Appeal Communication to Board of  
Appeals and Interferences☐ Appeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s) (please  
Identify below):36 References  
Certificate of Express Mailing  
Return Receipt Postcard

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

DARBY &amp; DARBY P.C.

Signature

Printed name

S. Peter Ludwig

Date

January 21, 2005

Reg. No.

25,351



Docket No.: 05986/100M724-US1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Marcus B. Jones et al.

Application No.: 10/823,396

Confirmation No.: 3661

Filed: April 12, 2004

Art Unit: 1632

For: B. ANTHRACIS PREVENTION AND  
TREATMENT; MUTANT B. ANTHRACIS  
LACKING LUXS ACTIVITY AND  
FURANONE INHIBITION OF GROWTH,  
AI-2 QUORUM SENSING, AND TOXIN  
PRODUCTION

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each document on the PTO/SB/08 is attached.

A concise explanation of relevance of the items listed on form PTO/SB/08 is given for only non-English language listed items.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: January 21, 2005

Respectfully submitted,

By 

S. Peter Ludwig

Registration No.: 25,351

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/823,396
				Filing Date	April 12, 2004
				First Named Inventor	Marcus B. Jones
				Art Unit	1632
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	05986/100M724-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Adjei, et al. Pharmaceutical Research 1990; 7:565-569 and 63:135-144 (leuprolide acetate), "Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers."###	
	CB	Bassler, Wright and Silverman. Mol. Microbiol. 1994; 13:273-286, "Multiple signaling systems controlling expression of luminescence in Vibrio harveyi: sequence and function of genes encoding a second sensory pathway."	
	CC	Benoist & Chambon, Nature 1981; 290:304-310, "Sequence requirements of the SV40 early promoter region."	
	CD	Braquet, et al. J. Cardiovascular Pharmacology 1989;13 (sup5): 143-146 (endothelin-1) "Effect of endothelin-1 on blood pressure and bronchopulmonary system of the guinea pig."	
	CE	Brinster RL, et al., Nature 1982; 296:39-42, "Regulation of metallothionein--thymidine kinase fusion plasmids injected into mouse eggs."	
	CF	Chang TK et al., (1993) Cancer Res. 53:1043-1050, "Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes."	
	CG	Chen at al., Nature 2001; 415:545-549, Chen, X., S. Schauder, N. Potler, A. Dorsselaer, I. Pelczer, B. Bassler, and F. M. Hughson. 2001. "Structural identification of a bacterial quorum-sensing signal containing boron." Nature 415:545-549	
	CH	Cote et al., Proc. Natl. Acad. Sci. USA 1983;80:2026-2030, "Generation of Human Monoclonal Antibodies Reactive with Cellular Antigens."	
	CI	Debs RJ, et al. J. Immunol. 1988; 140:3482-3488 (interferon- and tumor necrosis factor ) "Lung-specific delivery of cytokines induces sustained pulmonary and systemic immunomodulation in rats."	
	CJ	Greenberg, Hastings and Ulitzur. Arch. Microbiol. 1979; 120:87-91, "Not found on Medline, please provide reference."	
	CK	Greener, et al., Strategies in Mol. Biol. 1995 7:32, "Not found on Medline, please provide reference."	
	CL	Guerot-Fleury, A., et al. Gene. 1995;167:335-336, "Antibiotic resistance cassettes for Bacillus	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/823,396
				Filing Date	April 12, 2004
				First Named Inventor	Marcus B. Jones
				Art Unit	1632
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	05986/100M724-US1
Sheet	3	of	3		

		fluorescence dyes for measuring cell proliferation of lymphokine-activated killer (LAK) cells."	
	CK1	Wagner, et al., Proc. Natl. Acad. Sci. USA 1981; 78:1441-1445,	
	CL1	Yamamoto T, et al., Cell 1980;22:787-797, "Identification of a functional promoter in the long terminal repeat of Rous sarcoma virus."	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--